New Delhi, September 21: The National Pharmaceutical Pricing Authority (NPPA), the drug price regulator on Wednesday announced that it has fixed and revised the ceiling prices of as many as 39 drug formulations. With the new move, some drugs used in the treatment of cancer, hepatitis B, tuberculosis, measles and malaria are expected to get cheaper. The drug price regulator announced the reduction in a notification on its website saying, “NPPA has fixed/revised ceiling prices/Retail Prices of 39 scheduled formulations of Schedule-I under Drugs (Prices Control) Order, 2013 in related Notification /order dated 20.09.2017”. The NPPA said that the ceiling price of 18 scheduled formulations has been fixed, and that of 21 has been revised

A recent tweet by NPPA India states, “The NPPA caps the prices of 37 more formulations; total of 821 so far under NLEM, 2015”. The drug price regulator lowered the prices of various drug formulations that include TB drugs Rifabutin, Isoniazid, Flucaxanole (anti-fungal medication), Sumatriptan (for migraine), Iohexol (a contrast agent used during X-rays) and Hepatitis B immunoglobulin. That raised the number of drugs under price control to 821. A senior government official was quoted by ET saying that the recent move is expected to slash prices of some of these drugs, like Hepatitis B immunoglobulin, by as much as 20%.

“All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified plus goods and services tax as applicable, if any,” the NPPA said in its release.

As per reports, NPPA informed that manufacturers not complying with the ceiling price would be liable to deposit the overcharged amount along with interest under the provisions of the Drugs (Price Control) Order, 2013. It has been ordered that all the drug retailers will have to display the price list prominently in their premises.